In one paragraphArticle in Circulation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
M Elizabeth Moss *Division of Pulmonary Medicine (M.E.M., T.K., Y. Li, Y.K., Y.H., B.A. R., K.Y.), Boston Children's Hospital, Harvard Medical School, MA.ORCID 0000-0002-9761-7263 Timothy Klouda *Division of Pulmonary Medicine (M.E.M., T.K., Y. Li, Y.K., Y.H., B.A. R., K.Y.), Boston Children's Hospital, Harvard Medical School, MA.
Yan Li *Division of Pulmonary Medicine (M.E.M., T.K., Y. Li, Y.K., Y.H., B.A. R., K.Y.), Boston Children's Hospital, Harvard Medical School, MA.ORCID 0000-0003-4504-558X Yu LiuDepartment of Radiology, School of Medicine; Stanford Cardiovascular Institution, Stanford University, CA (Y. Liu, J.C.W.).ORCID 0000-0001-7110-127X Meng TanDivision of Cardiology, Department of Medicine, University of California, San Diego, La Jolla, CA (M.T.).
Yunhye KimDivision of Pulmonary Medicine (M.E.M., T.K., Y. Li, Y.K., Y.H., B.A. R., K.Y.), Boston Children's Hospital, Harvard Medical School, MA.ORCID 0009-0002-1804-571X Yuan HaoDivision of Pulmonary Medicine (M.E.M., T.K., Y. Li, Y.K., Y.H., B.A. R., K.Y.), Boston Children's Hospital, Harvard Medical School, MA.ORCID 0000-0003-2322-6806 Wen TianDivision of Pulmonary, Allergy and Critical Care Medicine, School of Medicine, Stanford University, CA (W.T., M.R.N.).
Mark R NicollsDivision of Pulmonary, Allergy and Critical Care Medicine, School of Medicine, Stanford University, CA (W.T., M.R.N.).ORCID 0000-0001-9473-7422 Joseph C WuDepartment of Radiology, School of Medicine; Stanford Cardiovascular Institution, Stanford University, CA (Y. Liu, J.C.W.).ORCID 0000-0002-6068-8041 Richard BucalaDivision of Rheumatology, Allergy and Immunology, Department of Medicine, Yale School of Medicine, New Haven, CT (R.B.).ORCID 0000-0001-5783-5736 Eungjoo LeeElectrical and Computer Engineering, College of Engineering, University of Arizona (E.L.).ORCID 0000-0001-6386-8470 Benjamin A RabyDivision of Pulmonary Medicine (M.E.M., T.K., Y. Li, Y.K., Y.H., B.A. R., K.Y.), Boston Children's Hospital, Harvard Medical School, MA.ORCID 0000-0003-2206-5748 Ke YuanDivision of Pulmonary Medicine (M.E.M., T.K., Y. Li, Y.K., Y.H., B.A. R., K.Y.), Boston Children's Hospital, Harvard Medical School, MA.ORCID 0000-0001-8085-5452 Funding
STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WAYNE I LENCER · 1986 to 2026
$32.4MRESPIRATORY RESEARCHT32HL007633 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI George R Washko · 1985 to 2026
$14.9MJoint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4MSuper-Resolution ImagingP30NS072030 · NINDS · HARVARD MEDICAL SCHOOL · PI REGEHR, WADE G · 2011 to 2020
$5.8MPericyte contribution to capillary remodeling in pulmonary arterial hypertensionR01HL171405 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Juan M Melero-Martin, Ke Yuan · 2024 to 2026
$2.4MPericytes differentiate into smooth muscle cells through HIF2a/SDF1 activationR01HL150106 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI YUAN, KE · 2021 to 2025
$2.2MMural cells contribution to vascular remodeling in flow induced pulmonary hypertensionK08HL171843 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Timothy Klouda · 2024 to 2026
$495kNHLBI NIH HHS K08 HL171843NHLBI NIH HHS R01 HL150106NHLBI NIH HHS R01 HL171405NHLBI NIH HHS T32 HL007633NIAMS NIH HHS P30 AR070253NIDDK NIH HHS P30 DK034854NINDS NIH HHS P30 NS072030
6 · The paper itselfAbstract
backgroundPulmonary arterial hypertension (PAH) is characterized by excessive remodeling of the distal arterioles and arteries, driven by endothelial cell (EC) apoptosis and uncontrolled mural cell proliferation. Increasing evidence suggests immune dysregulation in PAH, but one crucial part of the immune system, the pulmonary lymphatics, has been largely overlooked. Patients with idiopathic PAH (IPAH) often develop abnormal tertiary lymphoid structures adjacent to remodeled arteries, yet the role of lymphatics in PAH pathogenesis and vascular remodeling remains unclear.
methodsMice with lymphatic EC-specific fluorescent label (Prox1-CreERT2::Rosa26-LSL-tdT) or lymphatic EC-specific deletion of Vegfr3 (vascular endothelial growth factor receptor 3; Prox1-CreERT2::Vegfr3
resultsPulmonary lymphatic vessels proliferated, branched, and dilated in response to hypoxia. Vegfr3 inhibition using MAZ51 or lymphatic EC-specific Vegfr3 deletion reduced hypoxia-induced lymphangiogenesis and was associated with worsened PH, right ventricular hypertrophy, and impaired drainage. Comparative single-cell RNA sequencing analysis revealed upregulation of
conclusionsThese findings identify adaptive lymphangiogenesis as a protective response in experimental PH and reveal a previously unrecognized CD74-VEGFR3 signaling axis in lymphatic ECs. Targeting lymphatic dysfunction may represent a novel therapeutic strategy to improve outcomes in PAH.
Indexed as
Antigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class IIHypertension, PulmonaryHypoxiaLymphangiogenesisVascular Endothelial Growth Factor Receptor-3AnimalsDisease Models, AnimalEndothelial CellsHumansMaleMiceMice, Inbred C57BLMice, KnockoutRatsRats, Sprague-DawleyAntigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class IIinvariant chainVascular Endothelial Growth Factor Receptor-3capillary permeabilityendothelial cellshypertension, pulmonaryinflammationlymphangiogenesis
Identifiers
PMID42233213
PMCPMC13335411
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390